Article
AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.